Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
about
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
description
clinical trial
@en
klinisch onderzoek
@nl
name
Pembrolizumab and Dasatinib, I ...... table Minimal Residual Disease
@en
type
label
Pembrolizumab and Dasatinib, I ...... table Minimal Residual Disease
@en
prefLabel
Pembrolizumab and Dasatinib, I ...... table Minimal Residual Disease
@en
P4844
P6153
P1476
Phase II Study of Adding the A ...... table Minimal Residual Disease
@en
P3098
NCT03516279
P580
2018-10-03T00:00:00Z
P582
2021-08-31T00:00:00Z